121 related articles for article (PubMed ID: 10155313)
1. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication.
Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
Pharmacoeconomics; 1995 Mar; 7(3):238-41. PubMed ID: 10155313
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
Souêtre E; Qing W
Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
Drummond M; Davies L
Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
Gisselbrecht C; Prentice HG; Bacigalupo A; Biron P; Milpied N; Rubie H; Cunningham D; Legros M; Pico JL; Linch DC
Lancet; 1994 Mar; 343(8899):696-700. PubMed ID: 7510813
[TBL] [Abstract][Full Text] [Related]
5. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K; Matthews J; Young G; Lowenthal R; Baxter H; Arthur C; Bashford J; Brighton T; Cannell P; Dunlop L; Durrant S; Enno A; Eliadis P; Gill D; Gillett A; Gottlieb D; Januszewicz H; Joshua D; Leahy M; Schwarer A; Taylor K;
Leukemia; 2001 Sep; 15(9):1331-8. PubMed ID: 11516093
[TBL] [Abstract][Full Text] [Related]
6. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Seymour AM; de Campos E; Thatcher N; De Greve J; Cunningham D; Howell A; Tueni E; Bron DG; Steward WP; Berdel WE
Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy.
Mapelli V; Graf vond der Schulenburg JM; Laaser U; Allhoff PG; Rossi F
Pharmacoeconomics; 1994; 6 Suppl 2():27-35. PubMed ID: 10155593
[TBL] [Abstract][Full Text] [Related]
8. Overview of the lenograstim pharmacoeconomics programme.
Oster G; Menzin J; Richard D; Cour-Chabernaud V
Pharmacoeconomics; 1994; 6 Suppl 2():9-17. PubMed ID: 10155596
[TBL] [Abstract][Full Text] [Related]
9. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.
Menzin J; Oster G; Cour-Chabernaud V; Richard D
Pharmacoeconomics; 1994; 6 Suppl 2():53-60. PubMed ID: 10155595
[TBL] [Abstract][Full Text] [Related]
11. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
Dunn CJ; Goa KL
Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
[TBL] [Abstract][Full Text] [Related]
12. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of available clinical evidence - filgrastim compared with lenograstim.
Sourgens H; Lefrère F
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):510-8. PubMed ID: 21781651
[TBL] [Abstract][Full Text] [Related]
14. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
[TBL] [Abstract][Full Text] [Related]
15. Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.
Drummond M; Menzin J; Oster G
Pharmacoeconomics; 1994; 6 Suppl 2():18-26. PubMed ID: 10155592
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
17. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM).
Takagi T; Sawamura M; Sezaki T; Kashimura M; Tsuchiya J; Hotta T; Ogawa N; Hirashima K
Support Care Cancer; 2001 Jul; 9(5):397-9. PubMed ID: 11497396
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
